SBIO vs. GERM

Last updated Apr 2, 2026

Compare and contrast key facts about ALPS Medical Breakthroughs ETF (SBIO) and Amplify Treatments, Testing and Advancements ETF (GERM).

SBIO and GERM are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. SBIO is a passively managed fund by SS&C that tracks the performance of the S-Network Medical Breakthroughs Index. It was launched on Dec 31, 2014. GERM is a passively managed fund by Amplify that tracks the performance of the Prime Treatments, Testing and Advancements Index. It was launched on Jun 17, 2020. Both SBIO and GERM are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.

Performance

SBIO vs. GERM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ALPS Medical Breakthroughs ETF (SBIO) and Amplify Treatments, Testing and Advancements ETF (GERM). The values are adjusted to include any dividend payments, if applicable.

SBIO vs. GERM - Yearly Performance Comparison

	2026 (YTD)	2025	2024
SBIO ALPS Medical Breakthroughs ETF	3.20%	55.07%	-5.18%
GERM Amplify Treatments, Testing and Advancements ETF	0.00%	0.00%	0.00%

Returns By Period

SBIO

• 1D: 0.99%
• 1M: 3.89%
• YTD: 3.20%
• 6M: 36.23%
• 1Y: 95.78%
• 3Y*: 26.37%
• 5Y*: 1.76%
• 10Y*: 9.75%

GERM

• 1D: 0.00%
• 1M: 0.00%
• YTD: 0.00%
• 6M: 0.00%
• 1Y: 0.00%
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

SBIO vs. GERM - Expense Ratio Comparison

SBIO has a 0.50% expense ratio, which is lower than GERM's 0.68% expense ratio.

GERM

Amplify Treatments, Testing and Advancements ETF

SBIO

ALPS Medical Breakthroughs ETF

Return for Risk

SBIO vs. GERM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SBIO

SBIO Risk / Return Rank: 96
SBIO Sharpe Ratio Rank: 97
SBIO Sortino Ratio Rank: 97
SBIO Omega Ratio Rank: 94
SBIO Calmar Ratio Rank: 98
SBIO Martin Ratio Rank: 97

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SBIO vs. GERM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ALPS Medical Breakthroughs ETF (SBIO) and Amplify Treatments, Testing and Advancements ETF (GERM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	SBIO	GERM	Difference
Sharpe ratio Return per unit of total volatility	2.92	—	—
Sortino ratio Return per unit of downside risk	3.57	—	—
Omega ratio Gain probability vs. loss probability	1.45	—	—
Calmar ratio Return relative to maximum drawdown	5.66	—	—
Martin ratio Return relative to average drawdown	19.94	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	SBIO	GERM	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.92	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.05	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.29	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.23	—	—

Dividends

SBIO vs. GERM - Dividend Comparison

Neither SBIO nor GERM has paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017
SBIO ALPS Medical Breakthroughs ETF	0.00%	0.00%	3.55%	0.22%	0.00%	0.00%	0.00%	0.04%	2.79%	1.77%
GERM Amplify Treatments, Testing and Advancements ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

SBIO vs. GERM - Drawdown Comparison

The maximum SBIO drawdown since its inception was -63.06%, which is greater than GERM's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for SBIO and GERM.

Drawdown Indicators

	SBIO	GERM	Difference
Max Drawdown Largest peak-to-trough decline	-63.06%	0.00%	-63.06%
Max Drawdown (1Y) Largest decline over 1 year	-15.08%	0.00%	-15.08%
Max Drawdown (5Y) Largest decline over 5 years	-53.67%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-63.06%	—	—
Current Drawdown Current decline from peak	-13.79%	0.00%	-13.79%
Average Drawdown Average peak-to-trough decline	-28.70%	0.00%	-28.70%
Ulcer Index Depth and duration of drawdowns from previous peaks	4.28%	0.00%	+4.28%

Volatility

SBIO vs. GERM - Volatility Comparison

ALPS Medical Breakthroughs ETF (SBIO) has a higher volatility of 12.61% compared to Amplify Treatments, Testing and Advancements ETF (GERM) at 0.00%. This indicates that SBIO's price experiences larger fluctuations and is considered to be riskier than GERM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SBIO	GERM	Difference
Volatility (1M) Calculated over the trailing 1-month period	12.61%	0.00%	+12.61%
Volatility (6M) Calculated over the trailing 6-month period	22.09%	0.00%	+22.09%
Volatility (1Y) Calculated over the trailing 1-year period	33.43%	0.00%	+33.43%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	33.55%	0.00%	+33.55%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	33.34%	0.00%	+33.34%